Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-03-31 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-03-31 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-03-31 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-03-31 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2013 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2016-12-31 | 0.00% 10-K · filed 2017-02-24 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2016-08-05 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | 0.00% 10-K · filed 2017-02-24 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-06 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-02-24 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-02 | |||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-07 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-14 | |||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-13 | |||
| 2013-03-31 | 0.00% 10-Q · filed 2014-05-14 | |||
| 2012-12-31 | 0.00% 10-K · filed 2014-03-21 | |||
| 2012-09-30 | 0.00% 10-Q · filed 2013-11-13 | |||
| 2012-06-30 | 0.00% 10-Q · filed 2013-08-12 | |||
| 2012-03-31 | 0.00% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 0.00% 10-K · filed 2013-03-22 | |||
| 2011-09-30 | 0.00% 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |